Literature DB >> 29066121

Patterns of Intraosseous Recurrence After Stereotactic Body Radiation Therapy for Coxal Bone Metastasis.

Kei Ito1, Takuya Shimizuguchi2, Keiji Nihei2, Tomohisa Furuya2, Hiroaki Ogawa2, Hiroshi Tanaka3, Keisuke Sasai4, Katsuyuki Karasawa2.   

Abstract

PURPOSE: To analyze the detailed pattern of intraosseous failure after stereotactic body radiation therapy (SBRT) for coxal bone metastasis. METHODS AND MATERIALS: Patients treated with SBRT to coxal bone metastasis were identified by retrospective chart review. The SBRT doses were 30 Gy or 35 Gy in 5 fractions. A margin of 5 to 10 mm was added to the gross tumor volume to create the clinical target volume. We evaluated the presence or absence of intraosseous recurrence using magnetic resonance imaging. Intraosseous recurrences were assessed as "in-field" or "marginal/out-of-field." In addition, we measured the distance between the center of the recurrent tumor and the nearest edge of the initial bone metastasis in cases of marginal/out-of-field recurrence.
RESULTS: Seventeen patients treated for 17 coxal bone metastases were included. Median age was 64 years (range, 48-79 years). Coxal lesions involved the ilium in 14 cases, pubis in 3, and ischium in 4 (3 lesions crossed over multiple regions). Patients most commonly had renal cell carcinoma (29.4%), followed by lung, hepatic cell, and colorectal cancers (23.5%, 11.8%, and 11.8%, respectively). Median follow-up after SBRT was 13 months (range, 2-44 months). Among all 17 cases, 7 cases developed 8 intraosseous recurrences, including in-field recurrence in 1 case and marginal/out-of-field recurrences in 7 cases. Median time to intraosseous recurrence was 10 months (range, 2-35 months). Among 7 cases with marginal/out-of-field recurrence, mean distance to the center of the recurrent tumor from the nearest edge of the initial bone metastasis was 34 mm (range, 15-55 mm).
CONCLUSIONS: Most recurrences were observed out-of-field in the same coxal bone. These results suggest that defining the optimal clinical target volume in SBRT for coxal bone metastasis to obtain sufficient local tumor control is difficult.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29066121     DOI: 10.1016/j.ijrobp.2017.08.045

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Appropriate endpoints for stereotactic body radiotherapy for bone metastasis: Classification into five treatment groups.

Authors:  Kei Ito; Naoki Nakamura; Takuya Shimizuguchi; Hiroaki Ogawa; Katsuyuki Karasawa
Journal:  Rep Pract Oncol Radiother       Date:  2019-12-18

2.  PSMA PET/CT to evaluate response to SBRT for prostate cancer bone metastases.

Authors:  Igor Sadetski; Yael Eshet; Orit Kaidar-Person; Uri Amit; Liran Domachevsky; Tima Davidson; Ilana Weiss; Maoz Ben Ayun; Zvi Symon
Journal:  Rep Pract Oncol Radiother       Date:  2021-08-12

3.  SEOR SBRT-SG stereotactic body radiation therapy consensus guidelines for non-spine bone metastasis.

Authors:  F Lopez-Campos; J Cacicedo; F Couñago; R García; O Leaman-Alcibar; A Navarro-Martin; H Pérez-Montero; A Conde-Moreno
Journal:  Clin Transl Oncol       Date:  2021-10-11       Impact factor: 3.405

4.  Surgical Scar Recurrence of Bone Metastases to the Femur: A Case Report.

Authors:  Marc Gaudet; Kelly Linden; Jean-Michel Caudrelier; Kristopher Dennis
Journal:  Cureus       Date:  2018-09-29

Review 5.  Single-Fraction Radiotherapy (SFRT) For Bone Metastases: Patient Selection And Perspectives.

Authors:  Mauro Loi; Joost J Nuyttens; Isacco Desideri; Daniela Greto; Lorenzo Livi
Journal:  Cancer Manag Res       Date:  2019-11-05       Impact factor: 3.989

6.  Palliative Efficacy of High-Dose Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Painful Non-Spine Bone Metastases: A Propensity Score-Matched Analysis.

Authors:  Kei Ito; Kentaro Taguchi; Yujiro Nakajima; Hiroaki Ogawa; Keiko Nemoto Murofushi
Journal:  Cancers (Basel)       Date:  2022-08-19       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.